Fernandez-Fuertes, M.
Macías, J.
Corma-Gómez, A.
Rincón, P.
Merchante, N.
Gómez-Mateos, J.
Pineda, J. A.
Real, L. M.
Article History
Received: 15 November 2019
Accepted: 17 February 2020
First Online: 21 April 2020
Competing interests
: J.M. has been an investigator in clinical trials supported by Bristol-Myers Squibb, Gilead and Merck Sharp & Dome. He has received lectures fees from Gilead, Bristol-Myers Squibb, and Merck Sharp & Dome, and consulting fees from Bristol Myers-Squibb, Gilead, and Merck Sharp & Dome. J.A.P. reports having received consulting fees from Bristol-Myers Squibb, Abbvie, Gilead, Merck Sharp & Dome, and Janssen Cilag. He has received research support from Bristol-Myers Squibb, Abbvie and Gilead and has received lecture fees from Abbvie, Bristol-Myers Squibb, Janssen Cilag, and Gilead. The remaining authors report no conflict of interest.